Cerevel Therapeutics Holdings (CERE)
US Market

Cerevel Therapeutics Holdings (CERE) Financial Statements


Cerevel Therapeutics Holdings Financial Overview

Cerevel Therapeutics Holdings's market cap is currently ―. The company's EPS TTM is $-2.731; its P/E ratio is -15.13; Cerevel Therapeutics Holdings is scheduled to report earnings on July 30, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue----$ 0.00
Gross Profit-----
EBIT$ -127.63M$ -91.44M$ -94.63M$ -108.99M$ -110.43M
EBITDA$ -131.16M$ -94.00M$ -97.27M$ -112.40M$ -109.14M
Net Income Common Stockholders$ -132.66M$ -96.36M$ -99.53M$ -104.29M$ -92.81M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 990.97M$ 676.88M$ 736.43M$ 826.99M$ 892.03M
Total Assets$ 1.24B$ 821.96M$ 894.35M$ 930.35M$ 1.02B
Total Debt$ 368.61M$ 368.88M$ 369.13M$ 369.37M$ 369.57M
Net Debt$ -622.35M$ -308.00M$ -367.29M$ -457.62M$ -522.46M
Total Liabilities$ 569.55M$ 549.00M$ 543.85M$ 498.64M$ 496.58M
Stockholders Equity$ 673.75M$ 272.96M$ 350.50M$ 431.71M$ 521.24M
Cash Flow-
Free Cash Flow$ -98.32M$ -73.14M$ -79.38M$ -95.26M$ -87.93M
Operating Cash Flow$ -97.42M$ -72.63M$ -77.33M$ -94.92M$ -87.48M
Investing Cash Flow$ -150.21M$ 51.39M$ 61.75M$ 110.78M$ -26.73M
Financing Cash Flow$ 508.37M$ 1.20M$ 37.61M$ 1.44M$ 2.13M
Currency in USD

Cerevel Therapeutics Holdings Earnings and Revenue History

Cerevel Therapeutics Holdings Debt to Assets

Cerevel Therapeutics Holdings Cash Flow

Cerevel Therapeutics Holdings Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis